Clinical trials: Metastatic Colorectal Neoplasms
Colorectal Neoplasms, Anal, Colon, and Rectal Cancers
Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer
Current therapies for metastatic colorectal cancer only prolong life for approximately 2 years. A more innovative therapy that prolongs life significantly or even cures is needed.
- Trial name
- NCT00780988
- Testing
- Autologous tumor cell + CpG vaccine, Autologous hematopoietic and immune cell rescue (transplantation)
- Where
- United States
- Sponsor
- Stanford University
Colorectal Cancer
TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
The purpose of this study: To explore the comparative effectiveness of BIBF 1120 in terms of : Progression-free survival (PFS), objective response, overall survival Evaluate and compare safety
- Trial name
- AIO-KRK-0111 (NCT01362361)
- Testing
- mFOLFOX6 + BIBF 1120
- Where
- 12 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Colorectal Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103142
- Testing
- falimarev, inalimarev, sargramostim
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Michael Morse, MD
Metastatic Colorectal Cancer
PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer
The primary objective of the two phase PERMAD trial is the evaluation of the impact of a personalized marker-driven treatment approach with early detection of progression and modification of treatment on cytokines and angiogenic…
- Trial name
- PERMAD (NCT02331927)
- Testing
- Aflibercept
- Where
- 3 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University of Ulm
Solid Tumors, Gastric Cancer
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.
- Conditions
- Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer
- Trial name
- NCT06783569
- Testing
- JR8603
- Where
- 2 sites in China
- Volunteers
- 94 people
- Sponsor
- JiaRay Group
Colorectal Neoplasms, Trifluridine and Tipiracil
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
This trial is a randomized, double-blind, multinational Phase III study to evaluate the efficacy and safety of preemptive treatment with FTD/TPI compared with administration of placebo as follow-up, which is the standard of care…
- Conditions
- Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
- Trial name
- ALTAIR (NCT04457297)
- Testing
- trifluridine and tipiracil
- Where
- 39 sites in Japan, Taiwan
- Volunteers
- 243 people
- Sponsor
- National Cancer Center Hospital East
Colorectal Cancer
Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)
This observational study will assess the treatment duration, progression-free survival, reason for stopping treatment and patient and tumor characteristics of bevacizumab [Avastin] treatment in patients with metastatic colorectal…
- Trial name
- NCT01089413
- Testing
- bevacizumab [Avastin]
- Where
- 19 sites in Belgium
- Volunteers
- 201 people
- Sponsor
- Hoffmann-La Roche
Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
The purpose of this study is to use Immunochemotherapy +/- Hypofractionated Radiation for complete response in solid tumors
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, Metastatic Triple Negative Breast Cancer
- Trial name
- I-CREST (NCT01936961)
- Testing
- CTLA-4 Antibody, Hypofractionated Radiotherapy
- Where
- United States
- Sponsor
- Western Regional Medical Center
Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
- Conditions
- Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT07566897
- Testing
- L19IL2, Ruxolitinib
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Metastatic Colorectal Cancer
A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.
- Trial name
- RETRO-TAS (NCT04965870)
- Testing
- Trifluridine/Tipiracil
- Where
- 8 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Hellenic Study Group of Psychoneuroimmunology in Cancer
Colorectal Cancer
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent…
- Trial name
- NCT00017082
- Testing
- oxaliplatin
- Where
- 10 sites in United States
- Sponsor
- Prologue Research International
Metastatic Colorectal Carcinoma (mCRC)
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
The standard second-line treatment for metastatic colorectal cancer (mCRC) involves chemotherapy (FOLFOX or FOLFIRI) combined with an antiangiogenic agent, such as bevacizumab or aflibercept.
- Trial name
- NCT07150403
- Testing
- Oxaliplatin intravenous, 5 FU bolus, Folinic acid
- Where
- 45 sites in France
- Volunteers
- 74 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Liver Metastasis, Liver Neoplasms
A Prospective Study of a Subharmonic-Aided Pressure Estimate Technology for Early Prediction of Response to Systemic Therapy in Colorectal Cancer Liver Metastases
Colorectal cancer is a common type of cancer that often spreads to the liver. When cancer spreads to the liver, treatment becomes very difficult. Many patients will undergo chemotherapy to shrink the tumor.
- Conditions
- Colorectal Liver Metastasis, Liver Neoplasms, Colorectal Neoplasms
- Trial name
- NCT07583381
- Testing
- SHAPE
- Volunteers
- 107 people
- Sponsor
- The First Hospital of Jilin University
Colorectal Cancer
An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin
The overall purpose of this study is to determine the efficacy, safety and tolerability of indisulam in combination with irinotecan as a treatment for patients with metastatic colorectalcancer previously treated with…
- Trial name
- NCT00165867
- Testing
- E7070
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Eisai Limited
Colorectal Cancer
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- FOLFERA (NCT01205711)
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 4 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Cardiff University
Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Phase Ib dose escalation in advanced solid tumors to identify dose for Phase II dose expansion in advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer. Open-label, nonrandomized.
- Conditions
- Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II, Colorectal Cancer for Phase II
- Trial name
- NCT02703571
- Testing
- ribociclib, Trametinib
- Where
- 15 sites in United States, Australia and 5 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Colorectal Cancer
ANGIOPREDICT. ICORG 12-16, V3
Primary Objective: The primary objective is to validate previously identified predictive/prognostic genomic DNA and expression biomarkers of response to combination bvz treatments in K-ras mutant advanced CRC (a CRC) or…
- Trial name
- NCT01822444
- Testing
- Biomarker analysis
- Where
- 17 sites in Germany, Ireland
- Volunteers
- 76 people
- Sponsor
- Cancer Trials Ireland
Metastatic Colorectal Cancer
The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
This is a prospective, single-center, single-arm phase II clinical trial.This study aims to evaluate the safety and tolerability of stereotactic ablative radiotherapy (SABR) in combination with Fruquintinib and Tislelizumab, and…
- Trial name
- NCT04948034
- Testing
- Stereotactic Ablative Radiotherapy (SABR), Fruquintinib, Tislelizumab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
The purpose of this study is to investigate the safety and efficacy of temsirolimus as a single drug, and of temsirolimus in combination with irinotecan in chemotherapy resistant patients with KRAS mutated colorectal cancer.
- Trial name
- TIRASMUS (NCT00827684)
- Testing
- Irinotecan, Temsirolimus
- Where
- 2 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Vejle Hospital
Metastatic Colorectal Cancer (MCRC)
Phase I/II Combination With Irinotecan- Erbitux
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median…
- Trial name
- NCT00594984
- Testing
- Cetuximab, Irinotecan, Brivanib
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.